

## Supplementary Table 1 . Published studies

### **Crossover study**

- ⌚ **38 patients with COPD**
- ⌚ **Administration of 500 mg roflumilast or placebo once daily for 4 weeks**
- ⌚ **Collection of sputum samples before and after 2 and 4 weeks of treatment**
- ⌚ **Determination of differential and absolute cell counts in whole sputum samples**
- ⌚ **Determination of markers of inflammation in sputum supernatants and blood**
- ⌚ **Implementation of spirometry weekly**

### **14 studies**

- ⌚ **State the relationship between COPD and levels of CRP, fibrinogen, leucocytes, TNF-a and interleukins 6 and 8.**

### **2 placebo-controlled, double-blind, multicentre trials**

- ⌚ **2 different populations**
- ⌚ **Patients with COPD >40 years old, with - severe airflow limitation**
  - bronchitic symptoms
  - history of exacerbations
- ⌚ **1 Randomised - oral roflumilast 500 µg once per day**
  - placebo for 52 weeks
- ⌚ **Primary endpoints - change in prebronchodilator forced expiratory volume in 1 s (FEV1)**
  - moderate or severe rate of exacerbations